AstraZeneca Rejig Brings Baselga On Board
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.
You may also be interested in...
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.